UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines

Martin, M; Spielmann, M; Namer, M; duBois, A; Unger, C; Dodwell, D; Vodvarka, P; ... Zielinski, C; + view all (2003) Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. ANN ONCOL , 14 (8) 1246 - 1252. 10.1093/annonc/mdg339.

Full text not available from this repository.

Abstract

Background: To assess antitumor activity and toxicity of pemetrexed in metastatic breast cancer (MBC) patients previously treated with anthracyclines.Patients and methods: Seventy-seven MBC patients from 12 European institutions were entered into the study. Seventy-two patients were considered evaluable for response and toxicity. Forty-two patients were classified as anthracycline-failure (relapse >30 days after completion of a prior anthracycline regimen) and 30 as anthracycline-refractory (progression within 30 days after anthracycline therapy). Pemetrexed 600 mg/m(2) was administered intravenously every 3 weeks until progressive disease or unacceptable toxicity.Results: There were three complete and 12 partial responders [response rate 21% (95% confidence interval 12%)]. Response rates in the anthracycline-failure and anthracycline-refractory groups were 24% and 17%, respectively. A subset of 31 patients pretreated with anthracyclines and taxanes had a response rate of 26%. Median duration of response and median survival were 5.5 and 10.7 months, respectively (13 months in the failure group and 5.7 months for refractory). Grade 3/4 toxicities included neutropenia and thrombocytopenia in 56% and 19% of patients, respectively. Nine patients (12%) experienced neutropenic fever. Grade 3/4 nonhematological toxicities included skin rash (10%), nausea (12%), fatigue (10%) and stomatitis (5%).Conclusion: Our trial demonstrates pemetrexed to be active in breast cancer, with manageable toxicity. Activity of pemetrexed did not appear to be adversely affected by prior taxane, 5-fluorouracil or endocrine treatments.

Type: Article
Title: Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines
DOI: 10.1093/annonc/mdg339
Keywords: anthracyclines, breast cancer, pemetrexed, taxanes, MULTITARGETED ANTIFOLATE LY231514, FIRST-LINE, PACLITAXEL, DISODIUM, VINORELBINE, RECURRENT, CARCINOMA, THERAPY, TRIALS
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/351933
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item